Lene Andersen1, Søren Friis, Jesper Hallas, Pernille Ravn, Bjarne W Kristensen, David Gaist. 1. Department of Neurology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense, Denmark; Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Sdr. Boulevard 29, 5000, Odense, Denmark.
Abstract
AIM: Oral contraceptive use influences the risk for certain cancers. However, few studies have examined any link with risk of central nervous system tumours. We investigated the association between hormonal contraceptive use and glioma risk among premenopausal women in a population-based setting. METHODS: Using national administrative and health registries in Denmark to conduct a nationwide case-control study, we identified all women ages 15 to 49 years with a first time diagnosis of histologically verified glioma between 2000 and 2009. Each case was age-matched to eight population controls using risk set sampling. Based on prescription data, exposure until 2 years prior to the index date was categorized according to hormonal contraceptive type, i.e. combined oestrogen-progestagen or progestagen only, and duration of use (<1, 1 to <5, ≥5 years). We used conditional logistic regression to compute odds ratios (ORs) with 95% confidence intervals (CIs) for glioma associated with hormonal contraceptive use, adjusting for potential confounders. RESULTS: We identified 317 cases and 2126 controls. Ever use of hormonal contraceptive was associated with an OR of 1.5 (95% CI 1.2, 2.0) and the OR increased with duration of use (long term, ≥5 years: OR 1.9; 95% CI 1.2, 2.9). The association between long term hormonal contraceptive use and glioma risk was most pronounced for progestagen only therapy (OR 2.4; 95% CI 1.1, 5.1), especially when this regimen constituted the sole hormonal contraceptive therapy (OR 4.1; 95% CI 0.8, 20.8). CONCLUSION: Long term hormonal contraceptive use may increase the risk of glioma.
AIM: Oral contraceptive use influences the risk for certain cancers. However, few studies have examined any link with risk of central nervous system tumours. We investigated the association between hormonal contraceptive use and glioma risk among premenopausal women in a population-based setting. METHODS: Using national administrative and health registries in Denmark to conduct a nationwide case-control study, we identified all women ages 15 to 49 years with a first time diagnosis of histologically verified glioma between 2000 and 2009. Each case was age-matched to eight population controls using risk set sampling. Based on prescription data, exposure until 2 years prior to the index date was categorized according to hormonal contraceptive type, i.e. combined oestrogen-progestagen or progestagen only, and duration of use (<1, 1 to <5, ≥5 years). We used conditional logistic regression to compute odds ratios (ORs) with 95% confidence intervals (CIs) for glioma associated with hormonal contraceptive use, adjusting for potential confounders. RESULTS: We identified 317 cases and 2126 controls. Ever use of hormonal contraceptive was associated with an OR of 1.5 (95% CI 1.2, 2.0) and the OR increased with duration of use (long term, ≥5 years: OR 1.9; 95% CI 1.2, 2.9). The association between long term hormonal contraceptive use and glioma risk was most pronounced for progestagen only therapy (OR 2.4; 95% CI 1.1, 5.1), especially when this regimen constituted the sole hormonal contraceptive therapy (OR 4.1; 95% CI 0.8, 20.8). CONCLUSION: Long term hormonal contraceptive use may increase the risk of glioma.
Authors: Geoffrey C Kabat; Yikyung Park; Albert R Hollenbeck; Arthur Schatzkin; Thomas E Rohan Journal: Int J Cancer Date: 2011-02-15 Impact factor: 7.396
Authors: Dominique S Michaud; Valentina Gallo; Brigitte Schlehofer; Anne Tjønneland; Anja Olsen; Kim Overvad; Christina C Dahm; Rudolf Kaaks; Annekatrin Lukanova; Heiner Boeing; Madlen Schütze; Antonia Trichopoulou; Christina Bamia; Andreas Kyrozis; Carlotta Sacerdote; Claudia Agnoli; Domenico Palli; Rosario Tumino; Amalia Mattiello; H Bas Bueno-de-Mesquita; Martine M Ros; Petra H M Peeters; Carla H van Gils; Eiliv Lund; Kjersti Bakken; Inger T Gram; Aurelio Barricarte; Carmen Navarro; Miren Dorronsoro; Maria José Sánchez; Laudina Rodríguez; Eric J Duell; Göran Hallmans; Beatrice S Melin; Jonas Manjer; Signe Borgquist; Kay-Tee Khaw; Nick Wareham; Naomi E Allen; Konstantinos K Tsilidis; Isabelle Romieu; Sabina Rinaldi; Paolo Vineis; Elio Riboli Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-08-27 Impact factor: 4.254
Authors: Martha J Felini; Andrew F Olshan; Jane C Schroeder; Susan E Carozza; Rei Miike; Terri Rice; Margaret Wrensch Journal: Cancer Causes Control Date: 2008-09-03 Impact factor: 2.506
Authors: M Ewertz; L Mellemkjaer; A H Poulsen; S Friis; H T Sørensen; L Pedersen; J K McLaughlin; J H Olsen Journal: Br J Cancer Date: 2005-04-11 Impact factor: 7.640
Authors: M M Reigstad; I K Larsen; T Å Myklebust; T E Robsahm; N B Oldereid; A K Omland; S Vangen; L A Brinton; R Storeng Journal: Hum Reprod Date: 2015-06-24 Impact factor: 6.918
Authors: A E Howell; J W Robinson; R E Wootton; A McAleenan; S Tsavachidis; Q T Ostrom; M Bondy; G Armstrong; C Relton; P Haycock; R M Martin; J Zheng; K M Kurian Journal: BMC Cancer Date: 2020-06-03 Impact factor: 4.430
Authors: Amy Elizabeth Howell; Jie Zheng; Philip C Haycock; Alexandra McAleenan; Caroline Relton; Richard M Martin; Kathreena M Kurian Journal: Front Genet Date: 2018-11-12 Impact factor: 4.599